Alzheimer’s Disease Next Game Changer: TauRx Pharmaceutical’s Novel Tau Aggregation Inhibitor
The advancements in medicine, public health and living standards in recent decades have significantly increased the global life expectancy by more than six years — from 66.8 years in 2000 to 73.1 years in 2019. In tandem, the rise in life expectancy has also led to the growing prevalence of age-related diseases particularly Alzheimer’s disease and related dementias (ADRDs), which typically result from a variety of diseases and injuries that affect the brain.
Currently, ADRDs affect 55 million people worldwide, with Alzheimer’s disease accounting for 50–70 percent of all cases. This is concerning as ADRDs are known to have a severely debilitating effect on quality of life due to the gradual decline in cognitive functions, including memory, reasoning, and verbal capacity. In the same year, ADRDs are responsible for 33.1 million disability-adjusted life years (DALYs) lost, making it the seventh leading cause of mortality and morbidity among older adults globally.
Furthermore, the implications of ADRDs are profound and far-reaching, impacting societies and economies worldwide. In 2019, the global cost of dementia care was estimated to exceed $1.3 trillion, a figure that is forecasted to rise to $2.8 trillion by 2030. Notably, approximately 50 percent of these costs are attributed to care provided by informal caregivers, such as family members and close friends, with women accounting for 70 percent of this caregiving. These caregivers often bear a significant burden, providing an average of five hours of care and supervision per day — a commitment that brings emotional, physical, and financial challenges.
One of the hallmark pathological features of ADRDs is the accumulation of abnormal tau proteins in the brain. Normally, tau proteins help stabilize microtubules, which are essential for maintaining the structure and function of neurons. However, in ADRDs, abnormal chemical changes cause these tau proteins to detach from the microtubules and aggregate to other tau molecules, resulting into tangles (neurofibrillary tangles) inside neurons. These tau tangles disrupt the normal synaptic communication between neurons, leading to significant cell death and the subsequent cognitive decline observed in patients.
Given the central role of tau in the progression of ADRDs, emerging evidence suggests that targeting tau pathology has become a promising approach in the quest for new and effective treatments. TauRx Pharmaceuticals, a leader in Alzheimer’s disease research, has focused on this approach. The company’s innovative drug, hydromethylthionine mesylate (HMTM), is a novel tau aggregation inhibitors (TAIs) designed to be an affordable, accessible, oral therapy that targets the formation of tau tangles in the brain. The 4mg oral tablet works by promoting he dissolution of existing tau tangles and prevent further aggregation of tau proteins, thereby preserving neuronal function and slowing cognitive decline.
Founded in Singapore in 2002, TauRx Pharmaceuticals has dedicated itself to developing treatments for neurodegenerative diseases, particularly those involving tau pathology. The company’s commitment to addressing the unmet needs of Alzheimer’s patients is underscored by its extensive patent portfolio. TauRx holds “composition of matter” patents and “use” patents that cover the application of its TAIs for the treatment and prevention of Alzheimer’s disease and frontotemporal dementia (FTD). With 836 granted patents and 120 pending, TauRx has established a strong intellectual property position that not only protects its innovative therapies but also positions the company as a leader in the field.
Moreover, TauRx’s lead compound, HMTM is the only drug targeting tau for Mild Cognitive Impairment. It has shown promise in clinical trials, with the Phase 3 LUCIDITY trial demonstrating its potential to slow cognitive decline in patients with mild cognitive impairment and mild to moderate Alzheimer’s disease. Additionally, the UK’s Medicines and Healthcare products Regulatory Agency has accepted the company’s Marketing Authorization Application for HMTM, and they are working closely to accelerate the availability of this medicine in the UK.
While developing effective treatments is crucial, early diagnosis of ADRDs is equally important in managing the disease. The current diagnostic pathway for AD is often slow and outdated, relying on technology developed decades ago. This creates bottlenecks, particularly at the point of specialist referral, where long wait times can delay diagnosis.
Recognizing this, TauRx has collaborated with Genting Berhad Malaysia to establish GT Diagnostics, with the vision of transforming the diagnostic landscape and market for dementia. GT Diagnostics is focused on developing much-needed tools that support early diagnosis and monitoring of dementia’s progression. These patented digital tools are designed to be accessible and readily deployable, ranging from home-based well-being apps to professional tools for experts. By making these tools available through various service providers — including financial and professional services, personal advice and support, residential and non-residential care, and specialized dementia centers — GT Diagnostics aim to bring dementia diagnostics into the 21st century, enabling timely intervention and better disease management.
As the global burden of ADRDs is projected to reach 78 million by 2030 and 139 million by 2050, the importance of innovation in treatment and diagnosis cannot be overstated. TauRx Pharmaceuticals is at the forefront of this effort, leveraging its strong intellectual property portfolio to protect groundbreaking therapies like HMTM. Their focus on improving diagnostic tools promises to enhance the speed and accuracy of diagnosis, ensuring that innovative treatments can be administered earlier and more effectively, ultimately improving patient outcomes.
